Only 16.64% of the stock of Proteostasis Therapeutics is held by institutions. >Historical Ratings The table shows the mean historical analyst recommendation for the current period, along with the previous 1, 2, and 3 periods. Proteostasis Therapeutics EPS beats by $0.02, Proteostasis Therapeutics Reports Third Quarter 2020 Financial Results. Do Not Sell My Information. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. You may vote once every thirty days. Identify stocks that meet your criteria using seven unique stock screeners. Learn more. View analyst ratings for Proteostasis Therapeutics or view top-rated stocks. Proteostasis Therapeutics, Inc. (PTI) estimates and forecasts To see all exchange delays and terms of use please see disclaimer. Abrahams covers the … MarketBeat just released five new trading ideas, but Proteostasis Therapeutics wasn't one of them. Low $2 High $8. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. MarketBeat's community ratings are surveys of what our community members think about Proteostasis Therapeutics and other stocks. In a report issued on April 24, Brian Abrahams from RBC Capital reiterated a Buy rating on Proteostasis Therapeutics (PTI – Research Report), with a price target of $7.00.The company’s shares closed last Friday at $1.31. Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI.". MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Get the latest Zacks research report on PTI — FREE 10 ETFs With Most Upside To Analyst Targets The average price target represents a … 4 Wall Street analysts have issued ratings and price targets for Proteostasis Therapeutics in the last 12 months. Export data to Excel for your own analysis. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 The official website for Proteostasis Therapeutics is www.proteostasis.com. The company earns $-59,130,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.17) by $0.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. W&T Offshore Inc. analyst ratings, historical stock prices, earnings estimates & actuals. You can opt out at any time. The company can be reached via phone at 617-225-0096 or via email at [email protected]. Do Hedge Funds Love Proteostasis Therapeutics, Inc. (PTI)? It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. Fundamental company data provided by Zacks Investment Research. Man Who Predicted March 2020 Crash Makes Bold Tech Stock Prediction. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy.". Learn more. The projected low price target is $3 while the price target rests at a high of $8. Proteostasis Therapeutics Inc (NASDAQ:PTI) shares dropped 5.7% during mid-day trading on Tuesday . Fundamental company data provided by Zacks Investment Research. Looking for new stock ideas? All times are ET. The average price target is $5.20, with a high forecast of $8.00 and a low forecast of $3.00. Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. They called the 2020 crash 45 days early. Please log in to your account or sign up in order to add this asset to your watchlist. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. View which stocks are hot on social media with MarketBeat's trending stocks report. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Stockholders Approve Business Combination with Yumanity Therapeutics, Inc.; Board Sets Reverse Stock Split Ratio, Yumanity Therapeutics to Raise $33.6 Million PIPE Contingent on Completion of Reverse Merger with Proteostasis. Their average twelve-month price target is $4.67, predicting that the stock has a possible downside of 73.74%. Asad Umar was removed and persons from the IMF and World Bank were brought through a conspiracy to … The average of Bloomberg consensus 12-month price targets implies an upside of 2.9%. Learn everything you need to know about successful options trading with this three-part video course. According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 12.2% and a 55.7% success rate. Please log in to your account or sign up in order to add this asset to your watchlist. All 25 analysts tracking the company have a ‘buy’ rating on the stock. Proteostasis Therapeutics does not currently pay a dividend. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Proteostasis Therapeutics has received no research coverage in the past 90 days. Some companies that are related to Proteostasis Therapeutics include Hypera (HYPMY), Apellis Pharmaceuticals (APLS), Insmed (INSM), Legend Biotech (LEGN), Karuna Therapeutics (KRTX), Agios Pharmaceuticals (AGIO), MorphoSys (MOR), Amicus Therapeutics (FOLD), Pacira BioSciences (PCRX), Rocket Pharmaceuticals (RCKT), Alkermes (ALKS), OPKO Health (OPK), ALX Oncology (ALXO), Corcept Therapeutics (CORT) and Viela Bio (VIE).